ClinicalTrials.gg
RecruitingNCT05789017Updated May 28, 2024

Treatment Strategies for IgG4-RD Patients With Internal Organ Involvement

An interventional study of Prednisone and Mycophenolate Mofetil and Mycophenolate Mofetil in Autoimmune Diseases, sponsored by Peking Union Medical College Hospital. Recruiting at 1 site in China. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2024-05-28.

Primary conditionImmunoglobulin G4-Related DiseaseRegistry: Autoimmune DiseasesReclassifiedWhy we changed it
Registry
Autoimmune Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Immunoglobulin G4-Related Disease
Why
  1. The study's title name Immunoglobulin G4-Related Disease, a narrower term within Autoimmune Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Peking Union Medical College Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.
  • Registered 8 months after the study started (first participant enrolled Jul 2022, registered Mar 2023).
  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital — 7 open to participants now, 7 under way, 1 of them phase 3. Immunoglobulin G4-Related Disease · Peking Union Medical College Hospital.

Planned enrollment
7th of 11
60 · median 74
Started
2022
with 1 other
No phase
4 of 15
2 open now
Registered
10th of 15
by date

Among the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, this one is the 7th largest by planned enrollment of the 11 interventional ones that give a count, is one of 2 that started in 2022, is one of 4 with no phase, and was the 10th registered.

Immunoglobulin G4-Related Disease

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

Browse Immunoglobulin G4-Related Disease studies →

Open to participants now

7 of the 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 27 Immunoglobulin G4-Related Disease studies recruiting now, 11 (41%) set no upper age limit and 13 (48%) stop at 75 or younger; 3 take children under 18; 3 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Immunoglobulin G4-Related Disease by Peking Union Medical College Hospital, or all of them as a file.
02

Study summary

This study has been designed as a 18-month, open-label randomized controlled clinical trial. The study aims to compare the efficacy and safety of two treatment strategies in active IgG4-RD patients with internal organ involvement during maintenance remission period: low dose mycophenolate mofetil group and leflunomide group.

Read the detailed description

60 active IgG4-RD patients with internal organ involvement are enrolled in this study and accept the combination treatment of glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months. During remission maintenance period, pateints are randomly divided into two groups at a 1:1 ratio: patients in group I are treated with low dose mycophenolate mofetil (1-1.5g/day) and patients in group Ⅱ accept the treatment of leflunomide (20 mg/day). Patients in two groups will be followed up for another 12 months, and clinical evaluations, laboratory tests, image examinations and IgG4-RD responder index (RI) will be recorded during follow up. The primary endpoint is the difference of relapse rate between two groups at 18 months. The secondary endpoints are relapse time, response rate and side effects.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

Keywords

  • Immunoglobulin G4-Related Disease
  • treatment strategies
  • relapse
  • leflunomide
  • mycophenolate mofetil
04

In context

Immunoglobulin G4-Related Disease Reclassified

73 studies on the registry are indexed under Immunoglobulin G4-Related Disease; 40 are open to participants now.

This study's planned enrollment of 60 is above the median of 48 across 52 interventional studies indexed under Immunoglobulin G4-Related Disease.

Browse Immunoglobulin G4-Related Disease studies →

Lead sponsor

Peking Union Medical College Hospital is the lead sponsor of 1,158 studies on the registry; 477 are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 0 (0%) have results posted.

Compared within Immunoglobulin G4-Related Disease, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Autoimmune Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

    1. Fulfillment of the 2019 American College of Rheumatology/European League against Rheumatology (ACR/EULAR) IgG4-related disease classification criteria; 2. Newly-onset or patients who requires initiation or continuation of treatment.

Exclusion criteria

Exclusion Criteria:

    1. Patients who were diagnosed as other diseases; 2. Patients who were diagnosed as malignant diseases; 3. Pregnant and lactating women; 4. Active infection: , , , TB; 5. Severe irreversible damage of organ function; 6. Receipt of any biologic therapy or agent other than GCs.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Group I

    Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months. Afterwards, patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.

    Drug: Prednisone and Mycophenolate Mofetil · Drug: Mycophenolate Mofetil

  • Experimental
    Group II

    Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months. Afterwards, patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.

    Drug: Prednisone and Mycophenolate Mofetil · Drug: Leflunomide

Interventions

  • DrugPrednisone and Mycophenolate Mofetil

    Drug pages: PrednisoneStudies of PrednisonePrednisone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · Mycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients are treated with glucocorticoids and mycophenolate mofetil in remission induction period (6 months), during which glucocorticoids are tapered regularly and discontinued in 6 months.

  • DrugMycophenolic AcidStudies of Mycophenolic AcidMycophenolic Acid pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients are treated with low dose mycophenolate (1-1.5g/day) during remission maintenance period for 12 months.

  • Patients are treated with leflunomide (20 mg/day) during remission maintenance period for 12 months.

07

What researchers measure

Primary outcomes

  1. The difference of relapse rate of IgG4-RD between two groups in 18 months.

    The definition of relapse: elevation of IgG4-RD Responder Index ≥ 2 points; new organ involvement or recurrence, with or without elevation of serum IgG4 levels.

    Time frame: 18 months

Secondary outcomes

  1. The difference of the time at baseline to first relapse between two groups.

    Time frame: 18 months

  2. Response rate to the treatment of the two groups.

    Complete response rate; Partial response rate; No response

    Time frame: 18 months

  3. Side effects

    Any side effects caused by treatments for IgG4-RD.

    Time frame: 18 months

08

Study locations

1 of 1 sites recruiting
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Dec 2024, 29 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 16, 2023
First posted
Mar 29, 2023
StartActual
Jul 1, 2022
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2024
Last update
May 28, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05789017
Responsible party
Wen Zhang (Professor, Peking Union Medical College Hospital) — Principal investigator
First posted
Mar 29, 2023
Start date
Jul 1, 2022
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2024 (estimated)
Last update
May 28, 2024

Study contacts

Yunyun Fei, MD
Contact
feiyunyun@pumch.cn
01069159953
Wen Zhang, MD
principal investigator · Peking Union Medical College Hospital

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Mycophenolic Acid · Leflunomide

Start the discussion